12 Month Price Forecast For KPTI
Distance to KPTI Price Forecasts
KPTI Price Momentum
๐ค Considering Karyopharm (KPTI)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 11, 2025 3:54 AM UTC
KPTI Analyst Ratings & Price Targets
Based on our analysis of 13 Wall Street analysts, KPTI has a bullish consensus with a median price target of $5.00 (ranging from $2.00 to $7.00). The overall analyst rating is Strong Buy (8.3/10). Currently trading at $0.62, the median forecast implies a 702.6% upside. This outlook is supported by 6 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Edward White at HC Wainwright & Co., projecting a 1,023.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
KPTI Analyst Consensus
KPTI Price Target Range
Latest KPTI Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for KPTI.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Feb 10, 2025 | RBC Capital | Brian Abrahams | Outperform | Reiterates | $3.00 |
Jan 15, 2025 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $7.00 |
Nov 6, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $7.00 |
Nov 6, 2024 | Piper Sandler | Christopher Raymond | Overweight | Maintains | $5.00 |
Nov 1, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $7.00 |
Aug 7, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $7.00 |
Aug 7, 2024 | Baird | Mitch Collett | Outperform | Maintains | $5.00 |
Aug 7, 2024 | RBC Capital | Brian Abrahams | Outperform | Reiterates | $3.00 |
Jun 28, 2024 | HC Wainwright & Co. | Edward White | Buy | Maintains | $7.00 |
Jun 3, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $8.00 |
May 9, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $8.00 |
Mar 1, 2024 | HC Wainwright & Co. | Edward White | Buy | Maintains | $8.00 |
Nov 3, 2023 | RBC Capital | Brian Abrahams | Outperform | Maintains | $3.00 |
Nov 3, 2023 | Piper Sandler | Christopher Raymond | Overweight | Maintains | $5.00 |
Aug 7, 2023 | Morgan Stanley | Michael Ulz | Equal-Weight | Maintains | $4.00 |
Aug 3, 2023 | RBC Capital | Brian Abrahams | Outperform | Maintains | $4.00 |
Aug 3, 2023 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $10.00 |
Aug 3, 2023 | Piper Sandler | Christopher Raymond | Overweight | Maintains | $7.00 |
Jul 26, 2023 | Wedbush | David Nierengarten | Neutral | Maintains | $4.00 |
Jul 26, 2023 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $10.00 |
Stocks Similar to Karyopharm Therapeutics Inc
The following stocks are similar to Karyopharm based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Karyopharm Therapeutics Inc (KPTI) Financial Data
Karyopharm Therapeutics Inc has a market capitalization of $79.03M with a P/E ratio of -0.5x. The company generates $148.44M in trailing twelve-month revenue with a -58.9% profit margin.
Revenue growth is +7.7% quarter-over-quarter, while maintaining an operating margin of -67.8% and return on equity of +105.1%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Karyopharm Therapeutics Inc (KPTI) Company Overview
About Karyopharm Therapeutics Inc
Develops drugs for cancer treatment.
Karyopharm Therapeutics Inc. operates as a commercial-stage pharmaceutical company focused on discovering, developing, and commercializing novel drugs targeting nuclear export mechanisms. The company generates revenue primarily through the commercialization of its lead compound, XPOVIO, and other developing drug candidates through various licensing and distribution agreements with partners for oncology indications.
The company's pipeline includes several promising compounds like Selinexor and ELTANEXOR, targeting various hematological and solid tumors. Karyopharm has strategic collaborations with notable pharmaceutical companies, enhancing its development capabilities and market reach. Established in 2008 and based in Newton, Massachusetts, Karyopharm is positioned to capitalize on the growing demand for innovative cancer therapies.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
325
CEO
Mr. Richard A. Paulson M.B.A.
Country
United States
IPO Year
2013
Website
www.karyopharm.comKaryopharm Therapeutics Inc (KPTI) Latest News & Analysis
Karyopharm Therapeutics granted 28,000 restricted stock units to three new hires, signaling growth and investment in talent as a commercial-stage cancer therapy company.
The granting of RSUs to new hires indicates Karyopharm's commitment to talent acquisition, potentially driving innovation and growth, which can enhance shareholder value.
Karyopharm Therapeutics anticipates top-line data from the Phase 3 SENTRY trial for Selinexor in myelofibrosis in 2H 2025. Preliminary 2024 revenues estimated at $145M, with $113M from XPOVIO.
The upcoming Phase 3 SENTRY trial data could reshape myelofibrosis treatment, impacting Karyopharm's market position. Leadership changes and projected revenues indicate strategic shifts and growth potential.
Karyopharm Therapeutics Inc. has appointed Lori Macomber as Executive Vice President, Chief Financial Officer, and Treasurer, effective January 3, 2025.
Leadership changes can impact a company's strategic direction and financial stability, influencing investor confidence and stock performance in Karyopharm Therapeutics.
Karyopharm Therapeutics has appointed Brendan Strong as Senior VP of Investor Relations and Corporate Communications, enhancing its leadership in investor engagement.
Brendan Strong's appointment may enhance Karyopharm's communication strategy, potentially improving investor confidence and attracting interest in its cancer therapies.
Karyopharm Therapeutics is meeting with the FDA to discuss the treatment landscape for endometrial cancer and its Phase 3 XPORT-EC-042 trial implications.
Karyopharm's FDA discussions could impact its Phase 3 trial outcomes and regulatory approval, influencing stock performance and investor sentiment in the biotech sector.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on December 3 at 11:30 a.m.
Karyopharm's participation in the Piper Sandler Healthcare Conference may signal potential insights into future developments, impacting investor sentiment and stock performance.
Frequently Asked Questions About KPTI Stock
What is Karyopharm Therapeutics Inc's (KPTI) stock forecast for 2025?
Based on our analysis of 13 Wall Street analysts, Karyopharm Therapeutics Inc (KPTI) has a median price target of $5.00. The highest price target is $7.00 and the lowest is $2.00.
Is KPTI stock a good investment in 2025?
According to current analyst ratings, KPTI has 6 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.62. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for KPTI stock?
Wall Street analysts predict KPTI stock could reach $5.00 in the next 12 months. This represents a 702.6% increase from the current price of $0.62. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Karyopharm Therapeutics Inc's business model?
Karyopharm Therapeutics Inc. operates as a commercial-stage pharmaceutical company focused on discovering, developing, and commercializing novel drugs targeting nuclear export mechanisms. The company generates revenue primarily through the commercialization of its lead compound, XPOVIO, and other developing drug candidates through various licensing and distribution agreements with partners for oncology indications.
What is the highest forecasted price for KPTI Karyopharm Therapeutics Inc?
The highest price target for KPTI is $7.00 from Edward White at HC Wainwright & Co., which represents a 1,023.6% increase from the current price of $0.62.
What is the lowest forecasted price for KPTI Karyopharm Therapeutics Inc?
The lowest price target for KPTI is $2.00 from at , which represents a 221.0% increase from the current price of $0.62.
What is the overall KPTI consensus from analysts for Karyopharm Therapeutics Inc?
The overall analyst consensus for KPTI is bullish. Out of 13 Wall Street analysts, 6 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $5.00.
How accurate are KPTI stock price projections?
Stock price projections, including those for Karyopharm Therapeutics Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.